The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2024

Filed:

Dec. 15, 2020
Applicant:

Yale University, New Haven, CT (US);

Inventors:

David A. Spiegel, New Haven, CT (US);

Patrick McEnaney, Jupiter, FL (US);

Kelly Fitzgerald, Upton, MA (US);

Assignee:

YALE UNIVERSITY, New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/55 (2017.01); A61K 31/194 (2006.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); C07D 249/04 (2006.01); C07D 249/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/55 (2017.08); A61K 31/194 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61K 47/54 (2017.08); C07D 249/04 (2013.01); C07D 249/06 (2013.01);
Abstract

The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention.


Find Patent Forward Citations

Loading…